Meet The Professors: Pancreatic Cancer Edition, 2016 - Video 40Adjuvant treatment with gemcitabine and capecitabine
1:38 minutes.
TRANSCRIPTION:
DR TEMPERO: The most recent data we have in postoperative adjuvant therapy comes from the ESPAC-4 trial, which showed the gemcitabine and capecitabine had a superior survival to gemcitabine monotherapy. And that particular regimen that was given in that trial is a little tougher for the US population. So 1 option to consider when toxicity is a concern would be to use gemcitabine and capecitabine on a different schedule. |